Search
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalis an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsSJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...
Categories: P-glycoprotein substratesBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 SubstratesPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorvotuzumab mertansine
go.drugbank.com/drugs/DB12089InvestigationalLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates